Tags

Type your tag names separated by a space and hit enter

Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study.
Clin Infect Dis. 2004 Jun 15; 38(12):1716-23.CI

Abstract

Atovaquone-proguanil has been shown to be effective and well tolerated for malaria prophylaxis in residents of countries of endemicity and in nonimmune adult travelers, but data about traveling children are limited. In a randomized, open-label, multicenter prophylaxis trial, 221 nonimmune pediatric travelers (age, 2-17 years) received either atovaquone-proguanil or chloroquine-proguanil. Safety and clinical outcome were evaluated 7, 28, and 60 days after travel. By posttravel day 7, a total of 39 (35%) of 110 atovaquone-proguanil and 41 (37%) of 111 chloroquine-proguanil recipients reported > or =1 adverse event. The data indicate that, over the course of treatment, fewer atovaquone-proguanil recipients had treatment-related adverse events (8% vs. 14%), including gastrointestinal complaints (5% vs. 10%). Two subjects discontinued prophylaxis because of drug-related adverse events; both had received chloroquine-proguanil. Observed compliance with prophylaxis was similar before and during travel, but it was higher for atovaquone-proguanil in the posttravel period. No study participant developed malaria. Atovaquone-proguanil was well tolerated and is an important addition to the limited arsenal of prophylactic agents available to children.

Authors+Show Affiliations

Institut Pasteur, Lille, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

15227617

Citation

Camus, Daniel, et al. "Atovaquone-proguanil Versus Chloroquine-proguanil for Malaria Prophylaxis in Nonimmune Pediatric Travelers: Results of an International, Randomized, Open-label Study." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 38, no. 12, 2004, pp. 1716-23.
Camus D, Djossou F, Schilthuis HJ, et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. Clin Infect Dis. 2004;38(12):1716-23.
Camus, D., Djossou, F., Schilthuis, H. J., Høgh, B., Dutoit, E., Malvy, D., Roskell, N. S., Hedgley, C., De Boever, E. H., & Miller, G. B. (2004). Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 38(12), 1716-23.
Camus D, et al. Atovaquone-proguanil Versus Chloroquine-proguanil for Malaria Prophylaxis in Nonimmune Pediatric Travelers: Results of an International, Randomized, Open-label Study. Clin Infect Dis. 2004 Jun 15;38(12):1716-23. PubMed PMID: 15227617.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. AU - Camus,Daniel, AU - Djossou,Felix, AU - Schilthuis,Herbert J, AU - Høgh,Birthe, AU - Dutoit,Emmanuel, AU - Malvy,Denis, AU - Roskell,Neil S, AU - Hedgley,Corinne, AU - De Boever,Erika H, AU - Miller,Gerri B, AU - ,, Y1 - 2004/05/27/ PY - 2003/05/02/received PY - 2004/02/04/accepted PY - 2004/7/1/pubmed PY - 2004/10/1/medline PY - 2004/7/1/entrez SP - 1716 EP - 23 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 38 IS - 12 N2 - Atovaquone-proguanil has been shown to be effective and well tolerated for malaria prophylaxis in residents of countries of endemicity and in nonimmune adult travelers, but data about traveling children are limited. In a randomized, open-label, multicenter prophylaxis trial, 221 nonimmune pediatric travelers (age, 2-17 years) received either atovaquone-proguanil or chloroquine-proguanil. Safety and clinical outcome were evaluated 7, 28, and 60 days after travel. By posttravel day 7, a total of 39 (35%) of 110 atovaquone-proguanil and 41 (37%) of 111 chloroquine-proguanil recipients reported > or =1 adverse event. The data indicate that, over the course of treatment, fewer atovaquone-proguanil recipients had treatment-related adverse events (8% vs. 14%), including gastrointestinal complaints (5% vs. 10%). Two subjects discontinued prophylaxis because of drug-related adverse events; both had received chloroquine-proguanil. Observed compliance with prophylaxis was similar before and during travel, but it was higher for atovaquone-proguanil in the posttravel period. No study participant developed malaria. Atovaquone-proguanil was well tolerated and is an important addition to the limited arsenal of prophylactic agents available to children. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/15227617/Atovaquone_proguanil_versus_chloroquine_proguanil_for_malaria_prophylaxis_in_nonimmune_pediatric_travelers:_results_of_an_international_randomized_open_label_study_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/421086 DB - PRIME DP - Unbound Medicine ER -